TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

cMet is a well‐characterized oncogene that is the target of many drugs including small molecule and biologic pathway inhibitors, and, more recently, antibody–drug conjugates (ADCs). However, the clinical benefit from cMet‐targeted therapy has been limited. We developed a novel cMet‐targeted ‘third‐g...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Mol Oncol
Główni autorzy: Gymnopoulos, Marco, Betancourt, Oscar, Blot, Vincent, Fujita, Ryo, Galvan, Diana, Lieuw, Vincent, Nguyen, Sophie, Snedden, Jeanette, Stewart, Christine, Villicana, Jose, Wojciak, Jon, Wong, Eley, Pardo, Raul, Patel, Neki, D’Hooge, Francois, Vijayakrishnan, Balakumar, Barry, Conor, Hartley, John A., Howard, Philip W., Newman, Roland, Coronella, Julia
Format: Artigo
Język:Inglês
Wydane: John Wiley and Sons Inc. 2019
Hasła przedmiotowe:
Research Articles
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6944112/
https://ncbi.nlm.nih.gov/pubmed/31736230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12600
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy